Efficacy of Sailuotong ((sic)(sic)(sic)) on neurovascular unit in amyloid precursor protein/presenilin-1 transgenic mice with Alzheimer's disease

被引:0
作者
Sun, Linjuan [1 ]
Li, Chengfu [2 ]
Liu, Jiangang [1 ]
Li, Nannan [1 ]
Han, Fuhua [5 ]
Qiao, Dandan [1 ]
Tao, Zhuang [4 ]
Zhan, Min [1 ]
Chen, Wenjie [1 ]
Zhang, Xiaohui [1 ]
Tong, Chenguang [1 ]
Chen, Dong [1 ]
Qi, Jiangxia [1 ]
Liu, Yang [1 ]
Xiao, Liang [1 ]
Zheng, Xiaoying [3 ]
Zhang, Yunling [1 ]
机构
[1] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Neurol, Beijing 100091, Peoples R China
[2] China Populat & Dev Res Ctr, Beijing 100081, Peoples R China
[3] Peking Univ, Dept Inst Populat Res, Beijing 100087, Peoples R China
[4] China Acad Chinese Med Sci, Grad Sch, Beijing 100700, Peoples R China
[5] Beijing Univ Chinese Med, Grad Sch, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
Alzheimer disease; amyloid beta-protein precursor; presenilin-1; mice; transgenic; replenishing Qi and activating blood; neurovascular unit; Sailuotong; PROTEIN; BRAIN; MECHANISMS; MEDICINE; BLOOD; LRP-1;
D O I
10.19852/j.cnki.jtcm.20240203.007
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
OBJECTIVE: To discuss the influence of Sailuotong ((sic), SLT) on the Neurovascular Unit (NVUs) of amyloid precursor protein (APP)/presenilin-1(PS1) mice and evaluate the role of gas supplementation in activating blood circulation during the progression of Alzheimer's disease (AD). METHODS: The mice were allocated into the following nine groups: (a) the C57 Black (C57BL) sham-operated group (control group), (b) ischaemic treatment in C57BL mice (the C57 ischaemic group), (c) the APP/PS1 sham surgery group (APP/PS1 model group), (d) ischaemic treatment in APP/PS1 mice (APP/PS1 ischaemic group), (e) C57BL mice treated with aspirin following ischaemic treatment (C57BL ischaemic + aspirin group), (f) C57BL mice treated with SLT following ischaemic treatment (C57BL ischaemic + SLT group), (g) APP/PS1 mice treated with SLT (APP/PS1 + SLT group), (h) APP/PS1 mice treated with donepezil hydrochloride following ischaemic treatment (APP/PS1 ischaemic + donepezil hydrochloride group) and (i) APP/PS1 mice treated with SLT following ischaemic treatment (APP/ PS1 ischaemic + SLT group). The ischaemic model was established by operating on the bilateral common carotid arteries and creating a microembolism. The Morris water maze and step-down tests were used to detect the spatial behaviour and memory ability of mice. The hippocampus of each mouse was observed by haematoxylin and eosin (HE) and Congo red staining. The ultrastructure of NVUs in each group was observed by electron microscopy, and various biochemical indicators were detected by enzymelinked immunosorbent assay (ELISA). The protein expression level was detected by Western blot. The mRNA expression was detected by quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS: The results of the Morris water maze and step-down tests showed that ischemia reduced learning and memory in the mice, which were restored by SLT. The results of HE staining showed that SLT restored the pathological changes of the NVUs. The Congo red staining results revealed that SLT also improved the scattered orange-red sediments in the upper cortex and hippocampus of the APP/PS1 and APP/PS1 ischaemic mice. Furthermore, SLT significantly reduced the content of A beta, improved the vascular endothelium and repaired the mitochondrial structures. The ELISA detection, western blot detection and qRT-PCR showed that SLT significantly increased the vascular endothelial growth factor (VEGF), angiopoietin and basic fibroblast growth factor, as well as the levels of gene and protein expression of low-density lipoprotein receptor-related protein-1 (LRP-1) and VEGF in brain tissue. CONCLUSIONS: By increasing the expression of VEGF, SLT can promote vascular proliferation, up-regulate the expression of LRP-1, promote the clearance of A beta and improve the cognitive impairment of APP/PS1 mice. These results confirm that SLT can improve AD by promoting vascular proliferation and A beta clearance to protect the function of NVUs. (c) 2024 JTCM. All rights reserved.
引用
收藏
页码:289 / 302
页数:14
相关论文
共 36 条
  • [1] HDL from an Alzheimer's disease perspective
    Button, Emily B.
    Robert, Jerome
    Caffrey, Tara M.
    Fan, Jianjia
    Zhao, Wenchen
    Wellington, Cheryl L.
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (03) : 224 - 234
  • [2] The blood-brain barrier in neurodegenerative disease: a rhetorical perspective
    Carvey, Paul M.
    Hendey, Bill
    Monahan, Angela J.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2009, 111 (02) : 291 - 314
  • [3] Chinese Medicine Neuroaid Efficacy on Stroke Recovery A Double-Blind, Placebo-Controlled, Randomized Study
    Chen, Christopher L. H.
    Young, Sherry H. Y.
    Gan, Herminigildo H.
    Singh, Rajinder
    Lao, Annabelle Y.
    Baroque, Alejandro C.
    Chang, Hui Meng
    Hiyadan, John Harold B.
    Chua, Carlos L.
    Advincula, Joel M.
    Muengtaweepongsa, Sombat
    Chan, Bernard P. L.
    de Silva, H. Asita
    Towanabut, Somchai
    Suwanwela, Nijasri C.
    Poungvarin, Niphon
    Chankrachang, Siwaporn
    Wong, K. S. Lawrence
    Eow, Gaik Bee
    Navarro, Jose C.
    Venketasubramanian, Narayanaswamy
    Lee, Chun Fan
    Bousser, Marie-Germaine
    [J]. STROKE, 2013, 44 (08) : 2093 - 2100
  • [4] The transcription factor orthodenticle homeobox 2 influences axonal projections and vulnerability of midbrain dopaminergic neurons
    Chung, Chee Yeun
    Licznerski, Pawel
    Alavian, Kambiz N.
    Simeone, Antonio
    Lin, Zhicheng
    Martin, Eden
    Vance, Jeffery
    Isacson, Ole
    [J]. BRAIN, 2010, 133 : 2022 - 2031
  • [5] Dauberman WN, 2017, OMICS International, V7, P1
  • [6] RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease
    Donahue, John E.
    Flaherty, Stephanie L.
    Johanson, Conrad E.
    Duncan, John A., III
    Silverberg, Gerald D.
    Miller, Miles C.
    Tavares, Rosemarie
    Yang, Wentian
    Wu, Qian
    Sabo, Edmond
    Hovanesian, Virginia
    Stopa, Edward G.
    [J]. ACTA NEUROPATHOLOGICA, 2006, 112 (04) : 405 - 415
  • [7] Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
    Echeverria, Valentina
    Barreto, George E.
    Avila-Rodriguez, Marco
    Tarasov, Vadim V.
    Aliev, Gjumrakch
    [J]. CURRENT ALZHEIMER RESEARCH, 2017, 14 (11) : 1155 - 1163
  • [8] New Insights Into the Pathogenesis of Alzheimer's Disease
    Fan, Liyuan
    Mao, Chengyuan
    Hu, Xinchao
    Zhang, Shuo
    Yang, Zhihua
    Hu, Zhengwei
    Sun, Huifang
    Fan, Yu
    Dong, Yali
    Yang, Jing
    Shi, Changhe
    Xu, Yuming
    [J]. FRONTIERS IN NEUROLOGY, 2020, 10
  • [9] Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model
    Guttenplan, Kevin A.
    Weigel, Maya K.
    Adler, Drew, I
    Couthouis, Julien
    Liddelow, Shane A.
    Gitler, Aaron D.
    Barres, Ben A.
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [10] The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease
    Iadecola, Costantino
    [J]. NEURON, 2017, 96 (01) : 17 - 42